RecruitingNot ApplicableNCT06514495

Differential Effects of in Vivo and Virtual Exposure Therapy in Agoraphobia

Differential Effects of in Vivo and Virtual Exposure Therapy on the Interoception and Reactivity of Different Body Systems in Agoraphobia


Sponsor

Johannes Gutenberg University Mainz

Enrollment

68 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Anxiety disorders, including agoraphobia, are prevalent in the German population, leading affected individuals to avoid specific places like crowds or public transport. Although cognitive-behavioral therapy with exposure is an effective treatment, many patients resort to medication rather than therapy. Virtual Reality Exposure Therapy (VRET) shows promise in easing exposure treatment with customizable scenarios. Interoception (body symptom perception) and the endocannabinoid system are explored as factors in maintaining agoraphobia. Studies investigate how therapies like exposure (both in vivo and in VR) impact these factors and treatment outcomes. Interoception, especially in panic disorder patients, plays a crucial role, with accurate heartbeat perception linked to maintaining anxiety. The endocannabinoid system, affecting various functions, is studied for its role in therapy outcomes and its modulation of the body's stress response. The study aims to understand how these systems interact in agoraphobic patients and how therapy affects their functionality.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing real-world exposure therapy (facing feared situations in person) against virtual reality exposure therapy for people with agoraphobia (fear of open or crowded spaces), to see which approach works better and understand how the body responds during each. **You may be eligible if...** - You have a diagnosis of agoraphobia with or without panic disorder (experimental group) - OR you have social phobia (clinical control group) - OR you are a healthy person without any mental illness (control group) - A co-existing mild depression diagnosis is acceptable in the experimental and clinical control groups **You may NOT be eligible if...** - You have schizophrenia, bipolar disorder, substance dependence, dementia, eating disorders, PTSD, active major depressive episode, or personality disorder - You have significant physical health conditions such as cancer, cardiovascular disease, epilepsy, or autoimmune/metabolic conditions - You take psychiatric medications (antidepressants are an exception) or medications affecting the heart - You are currently in psychotherapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTherapy

Cognitive behavioral psychotherapy with exposure


Locations(1)

University Medical Center

Mainz, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06514495


Related Trials